BlackRock Ups Stake in MaxCyte to 9.75%
Company Announcements

BlackRock Ups Stake in MaxCyte to 9.75%

MaxCyte (MXCT) has released an update.

MaxCyte, Inc. has reported a significant change in share ownership, revealing that BlackRock, Inc. has crossed a threshold, now holding a combined total of 9.75% of voting rights as of September 17, 2024. This change includes both direct voting rights attached to shares and voting rights through financial instruments. The financial community may find this adjustment noteworthy as it could signal BlackRock’s increasing influence or strategic interest in MaxCyte.

For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyMaxCyte, Kamau Therapeutics enter strategic platform license agreement
TipRanks UK Auto-Generated NewsdeskMaxCyte Partners with Kamau Therapeutics to Advance Gene Therapies
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App